Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up

Abstract

Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up

Update on lobular lesions of the breast

“…[89][90][91][92] ILC appears to have a survival advantage compared to IBC-NST in the first 10-15 years after surgery; however, prognosis is worse for patients with ILC after this period. 90,92 In addition, patients with ILC are more likely to undergo mastectomy and have positive margins at surgical excision. 93 Large-scale studies have reported lower rates of pathological complete response to neoadjuvant therapy in ILC compared to IBC-NST, although this difference was no longer seen when cases were adjusted for tumour size, grade and ER/HER status in some series.…”

“…27,88 However, studies have shown that ILC has a different clinical presentation, prognosis and recurrence pattern with a predilection for bone and atypical sites for breast metastasis, such as the gastrointestinal tract, peritoneum and gynaecological tract. [89][90][91][92] ILC appears to have a survival advantage compared to IBC-NST in the first 10-15 years after surgery; however, prognosis is worse for patients with ILC after this period. 90,92 In addition, patients with ILC are more likely to undergo mastectomy and have positive margins at surgical excision.…”

“…Currently, standard treatment for ILC is similar to IBC–NST at the same clinical stage and receptor profile 27,88 . However, studies have shown that ILC has a different clinical presentation, prognosis and recurrence pattern with a predilection for bone and atypical sites for breast metastasis, such as the gastrointestinal tract, peritoneum and gynaecological tract 89–92 . ILC appears to have a survival advantage compared to IBC–NST in the first 10–15 years after surgery; however, prognosis is worse for patients with ILC after this period 90,92 .…”

Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas

“…Although ER+ ILC and IDC tumors are treated clinically as a single disease (9), recent studies have established ER+ ILC as a distinct disease with unique sites of metastasis, frequent presentation of multifocal disease, delayed relapses, and decreased long-term survival compared to ER+ IDC tumors (10)(11)(12)(13)(14). Large-scale studies from The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) have reported genomic and transcriptomic analyses on resected IDC and ILC tumors (15,16).…”

Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes

“…Clinically, ILC tumors have an indolent clinical course and grossly manifest as ill-defined masses or architectural distortion [ 5 ]. Additionally, ILC is generally more difficult to detect through standard imaging modalities such as mammography, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET), or ultrasounds compared to IDC [ [6] , [7] , [8] ].…”